Abstract

Enterovirus type 71 (EV71) and coxsackievirus A 16 (CA16) are the major pathogens of human hand, foot, and mouth disease (HFMD). In our previous study, intramuscular immunization with the inactivated EV71 vaccine elicited effective immunity, while immunization with the inactivated CA16 vaccine did not. In this report, we focused on innate immune responses elicited by inactivated EV71 and CA16 antigens administered intradermally or intramuscularly. The distributions of the EV71 and CA16 antigens administered intradermally or intramuscularly were not obviously different, but the antigens were detected for a shorter period of time when administered intradermally. The expression levels of NF-κB pathway signaling molecules, which were identified as being capable of activating DCs, ILCs, and T cells, were higher in the intradermal group than in the intramuscular group. Antibodies for the EV71 and CA16 antigens colocalized with ILCs and DCs in skin and muscle tissues under fluorescence microscopy. Interestingly, ILC colocalization decreased over time, while DC colocalization increased over time. ELISpot analysis showed that coordination between DCs and ILCs contributed to successful adaptive immunity against vaccine antigens in the skin. EV71 and/or CA16 antigen immunization via the intradermal route was more capable of significantly increasing neutralizing antibody titers and activating specific T cell responses than immunization via the intramuscular route. Furthermore, neonatal mice born to mothers immunized with the EV71 and CA16 antigens were 100% protected against wild-type EV71 or CA16 viral challenge. Together, our results provide new insights into the development of vaccines for HFMD.

Highlights

  • Previous studies of human enterovirus vaccines have substantially improved our knowledge of the immunology of viral attenuated and inactivated vaccines and advanced our understanding of vaccine mechanisms.[1]

  • The results obtained in these studies suggested that the inactivated Enterovirus type 71 (EV71) vaccine is capable of inducing immunity with clinical protective efficacy, while the coxsackievirus A 16 (CA16) vaccine is not[17,18]; these findings improved our understanding of various immunogenic pathways

  • It would be reasonable to infer that administration of the inactivated CA16 antigen via the intradermal route alone or together with the EV71 antigen might sequentially activate each innate and adaptive immunity component, potentially exerting a clinically protective effect similar to that induced by natural viral infection.[7,41]

Read more

Summary

Introduction

Previous studies of human enterovirus vaccines have substantially improved our knowledge of the immunology of viral attenuated and inactivated vaccines and advanced our understanding of vaccine mechanisms.[1]. Basic immunological studies have provided knowledge about the sensing of pathogenic antigens by pattern recognition receptors (PRRs) in epithelial tissues and the coordination of various innate immune cells for antigen presentation to T cells and data on the systematic mechanism of adaptive immunity that is activated by comprehensive signals from the innate immune response.[8,9]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call